Aktuellt
SENASTE
Redeye’s initial comment on the Q1 report was published earlier this morning. There were no sales, as expected. Progress continues as expected and awaits the results of the registration process. We continue to see that Moberg Pharma is on schedule for commercialization. We expect to decrease our valuation slightly c 10% after the report as we push some milestone payments into next year and higher capitalized R&D costs. The effects are minor as most of the company’s value is unrelated to near-term development.
LÄS MER
